Home / Industry Reports / Pharmaceutical Market Research
Sort By: Title Date Price

Biosimilars - Regulatory Framework and Pipeline Analysis

Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are getting the world wide attention as the cost of the innovative biologics are enormously high and even minimal reduction in price will reduce the healthcare spending substantially. All the countries are focusing on reducing the healthcare expenditure and biosimilars compliments to this goal.

$2995 Read More

Opioids Market Overview to 2023 - Opioids in Emerging Markets

The report provides analysis of new developments that will have a strong bearing on the use of opioids in pain management in emerging countries (Argentina, Brazil, China, India, Mexico, Russia and South Africa). Access to opioids is restricted under strict drug control policies and regulations overseeing controlled medicines due to their high abuse potential. Emphasis on restricting access to controlled drugs is much higher in emerging markets than in developed nations, resulting in a level of consumption that is too low to meet pain-control requirements even in cases of terminal illness.

$2995 Read More

Opioids Market Overview to 2023 - Opioids in Western Europe

The report provides an estimation of 2013 opioid revenues and forecast consumption and revenues until 2023 in the five major Western European countries: the UK, Germany, France, Italy and Spain. The estimated revenues for 2013 are highest in the UK, which held a share of 52%, followed by Germany with 20%. Spain had the lowest in terms of both consumption (3.3%) and revenues (2.2%). Their use for medicinal purposes has been highly controversial for several decades. Although recognized as potent painkillers, potential for misuse is high. As a result, all regulatory authorities strive to maintain a fine balance between enforcing strict regulations that will crack down on illicit usage but at the same time ensure accessibility for genuine medical purposes.

$2995 Read More

Pediatric Drug Development - Regulatory challenges and commercial opportunities

Although pediatrics represent around two-fifths of the global population the market for pediatric medicines remains relatively small (accounting for <10% of global pharmaceutical sales). Until pediatric legislation was introduced in the US (1997) and EU (2007) there has been little incentive for the pharma industry to evaluate drugs in children due to the low medical need of chronic illnesses and the high off-label use of generic drugs (Milne & Bruss, 2008).  Since the introduction of pediatric legislation there has been a substantial investment in pediatric research and the number of clinical trials performed in children has increased significantly.

$2995 Read More

Adaptive Licensing - A Holistic Approach to Drug Development and Regulation

Adaptive Licensing (AL) is a flexible approach to drug development and regulation, with two live pilot schemes accepted by the European Medicines Agency (EMA). The system acknowledges that levels of uncertainty will always surround innovative treatments. An initial license is granted at an earlier stage than possible under the traditional system, with less clinical information from Randomized Controlled Trials (RCTs).

$2996 Read More

Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases

More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of emergency admissions in elderly people is drug-related. There remains a lack of clinical data to support prescription decisions as relatively few medicines have been clinically evaluated in age-appropriate patients.

$3900 Read More

Vaccine Development Strategies - Refocusing Efforts to Address New Challenges

Vaccines are one of the most important healthcare advances and have saved millions of lives through immunizing against some of the most deadly diseases. With protection against a number of key viral and bacterial diseases now effectively generated, vaccine R&D is turning to areas of unmet need. Preventative vaccination in adults and against pathogens that affect the developing world is increasingly becoming a focus. Research into therapeutic vaccination for patients already affected by a disease is also gathering pace.

$3900 Read More

Telemedicine - The Future is Now for Moving Telemedicine into Mainstream Treatment

Telemedicine is a creation of the 20th century. First used primarily for military and space applications, it has been becoming more widespread in use in recent years. There are three main types of telemedicine applications: store-and-forward, remote monitoring and interactive services. Interest in telemedicine is growing globally, particularly in the fields of teleradiology, telepathology and teledermatology. Globally, cost is seen as the major barrier to telemedicine programs. In the US, telemedicine has been promoted as a way to serve rural populations, but in the next few years it is expected to spread to a much wider patient base.

$3900 Read More

Immunotherapy Development Strategies - An Evolving Market with Significant Potential but with Challenging Hurdles to Overcome

Although immunotherapy was first recognized over 100 years ago, it has only become an important therapeutic tool in recent decades. The immune system can be harnessed in one of several ways to tackle various diseases such as cancer, infection, auto-immune disease and inflammatory diseases. The complexity of the immune system has led to some intrinsic obstacles with clinical research, particularly in relation to targeting the right genes, identifying the appropriate patient population and accessing internal tissues for testing.

$3900 Read More

The Politics of Pharma - Washington, States and the Courts Impact on the Industry

Politics have a greater direct effect on the pharmaceutical industry than almost any other in the US, and correspondingly, pharma makes considerable investments in election campaigns. The November elections kept the face of Washington the same, with the re-election of President Obama, Democratic control of the Senate and Republican control of the House. However, the outcome of the elections will still impact the industry in a variety of ways. The Medical Device Excise Tax, a component of the 2010 health care reform legislation, survived a pre-election Congressional effort at repeal, but a coalition of House Republicans and Democrats from key states are looking to try again.

$3900 Read More

R&D Productivity - The State of Research and Development in the BioPharmaceutical Industry

As blockbusters go off patent and the pool of marketed products supporting pharmaceutical Research & Development (R&D) decline, questions about the future of R&D in the pharmaceutical and biotech industry arise. Where will funding come from? Is spend decreasing? If spend is decreasing, what impact is this having on R&D? What can be done to encourage innovation in the biotech and pharmaceutical industry? Is the biotech model of R&D better for innovation than the traditional pharmaceutical model? Gauging the overall growth of R&D in the pharmaceutical and biotech industry proves challenging in regards to stipulating the appropriate definition of variables by which this is measured.

$3900 Read More

Companion Diagnostics - Streamlining drug development and advancing personalized medicine

Personalized healthcare encompasses tailored diagnostics, treatment and management of illnesses and diseases. Although the concept has been around for many years, it is only with the advent of companion diagnostics that personalized healthcare has started to gain ground. Companion diagnostics can be used in screening, monitoring, diagnosing and treating patients and can allow for stratification of patients to maximize efficacy and minimize risk

$3900 Read More

Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy

The leading pharmaceutical players continue to face the combined threats of a difficult operating environment and patent losses while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands. However, the increasing size of the leading biopharmaceutical companies is necessitating their involvement in growing the numbers and size of deals year by year. This in itself, along with the rising financial firepower of the mid-tier players, has increased the level of competition for the most attractive targets.

$3900 Read More

Oncology Development Strategies - Considerable commercial potential but specific needs must be addressed

The oncology therapeutic area has seen significant development and advances over the last decade. However, oncology has one of the lowest overall clinical success rates of all therapy areas with only a third of oncology drugs that get to Phase III proceeding to approval. There are a number of factors that will affect the likelihood of success in oncology drug development and these must be taken into consideration when designing the clinical development plan. Oncology clinical trials tend to be more complex than those in other therapy areas, largely due to the number of endpoints that can be utilized, the growing need for adaptive trial design and the types of patients that are eligible for the clinical studies.

$3900 Read More

Biologics in the Emerging Markets - Ripe For Realization of the Commercial Potential - But Hurdles Still to Overcome

Biologics cover a diverse range of products and deliverables and have revolutionized the treatment of many diseases. The complexity of biologics has made their manufacture an expensive and lengthy process which has hindered uptake in many less developed healthcare markets. However, the global biologics market is rapidly growing and was estimated to be worth over $130 billion in 2010. Of the emerging markets, the BRIC markets offer the greatest potential for pharmaceutical growth, especially in biologics which represent a relatively untapped market in these countries. It is expected the BRIC markets will account for over 25% of global biologic revenues by 2015.

$3900 Read More

Electronic Health Records - Charting the Future of Health Care

Electronic Health Records have been in limited use since the 1960s, but their adoption received a major boost when they became more of a focus for the US government. In 2004, President Bush put forth the goal of having every American covered by an EHR within 10 years. In 2009, President Obama added the key element of funding under the American Recovery and Reinvestment Act. The EHR Meaningful Use Incentive programs funded under the ARA were further bolstered by programs in the 2010 health care reform legislation which promoted Accountable Care Organizations. After the results of the November elections and the Supreme Courts ruling upholding the individual mandate, the future for health care reform would look more sure.

$3900 Read More

The Digital Patient - A Snapshot of the Digital Landscape of Patients and Caregivers

The advent of mobile phones and other devices has opened up new channels for pharmaceutical marketers to reach patients and caregivers. The Pharma industry as a whole is late to the digital game so logically patients and caregivers have pre-existing expectations of the digital experience. Digital enables brands to deliver highly targeted information in a variety of forms. It creates the setting for a brand experience versus a promotional moment. This is a tremendous opportunity but not one without challenges one of the biggest obstacles being lack of clear direction from the FDA around appropriate use of social media.

$3900 Read More

Emerging Pharmaceutical Technologies - Stem cells

The report, Emerging Pharmaceutical Technologies - Stem cells has been written to support corporate strategy, new product development, business development, and R&D teams through its analysis of the trends being seen and the innovations taking place in this fast moving area. This report will support the corporate strategies and key decisions being made in this area through its analysis, insights, case studies, and company profiles included.

$3900 Read More

Accountable Care Organizations - A Building Block for the Future of Health Care

The Accountable Care Act promoted ACOs through a variety of programs: Comprehensive Primary Care Initiative, Partnerships for Patients Initiative, Pioneer and Advanced Payment ACO Models and Medicare Shared Savings Program for ACOs. The central program is the Medicare Shared Savings Program, under which ACOs gradually share in the cost savings they achieve through providing coordinated and consistent care to groups of Medicare beneficiaries while meeting quality targets. The focus of ACOs is coordinated care, ease-of-access, care management models, evidence-based care, technology use for data management, and clinical integration.

$3900 Read More

Clinical Development and Trial Design - Developing a Coherent Approach From Beginning to End

A good clinical development plan will ensure success throughout the product lifecycle. In todays cost constrained environment, the clinical development plan can help refine the trial process, encouraging cost and time efficiencies and ensuring a streamlined process throughout. The clinical development plan ties together all aspects of product development, enabling an incorporated approach to the clinical and commercial rationale of product development. A variety of approaches should be adopted to ensure a robust clinical development plan is developed.

$3900 Read More

Diversification in the Pharmaceutical Industry - Essential For Survival or an Unnecessary Distraction?

Pharmaceutical companies face the dual threats of industry specific difficulties driven by the innovation crisis, patent expiries and healthcare reform, coupled with the more generalized issues caused by the continuing global economic slowdown. The industry remains split on whether diversification or specialization is the key to building a successful business model in the face of these difficulties. On one hand some companies believe that diversification is necessary to survive and thrive in the current difficult operating environment and that it offers specific advantages going forward.

$3900 Read More

The Next Generation of Pharmaceutical Marketing Strategies - Understanding All of the Strategic Considerations Needed in the Age of Multiple Stakeholders

Pharmaceuticals save lives. They prevent more serious, life changing conditions, they prevent surgery, and they improve the quality of life for many patients. The environment in which these products are developed and commercialized is in a period of great transformation. Lacking a crystal ball, the industry as a whole is navigating through unchartered waters. Multiple factors are driving the need for industry-wide change. One of the biggest contributors is the escalating cost of healthcare. In an effort to stop and reverse this trend a great emphasis is being placed on improving the delivery of care and outcomes for patients.

$3900 Read More

Pharmaceutical Pricing Strategies - Changing approaches to meet challenging times

The current economic environment has created a number of challenges within the pharmaceutical market, with governments looking to reduce spending on healthcare and drugs. Consequently, prices have come under scrutiny, with many older products having discounts forced upon them and new drugs being subject to increasingly complex assessments in order to obtain the desired price. Novel pricing policies, such as value based pricing and external price referencing, are being employed by governments to regulate pharmaceutical prices and are expected to have a significant impact on prices and profitability in the future.

$3900 Read More

The Payer Landscape in the United States - The Pharmaceutical Industry Faces a Rapidly Changing Marketplace

Managed care began to be developed as early as 1917, with both private and government payers established by the mid-1960s. Medicare and Medicaid are the major government payers, with the health care reform legislation of 2010 providing changes for both. That said, private payers, such as regionals, nationals and blues plans, may take the brunt of the reform policies put in place. The health care reform legislation in 2010 was the product of extended debate and compromise. The legislation will mean huge changes for the insurance industry if it is enacted. However, the more controversial aspects of the legislation, particularly the Mandate for health insurance, have resulted in numerous challenges.

$3900 Read More

Reformulation Strategies - New Technologies Extend Use Beyond Lifecycle Management

Reformulation performs a key role in the pharmaceutical industry enabling companies to maximize their returns on investment while broadening treatment options and improving patient experience. Its potential to rejuvenate R&D pipelines in the future as new technologies emerge compliment its position as a key lifecycle management strategy. Reformulation will continue to be a much used lifecycle management strategy, enabling companies to boost sales before patent expiry and in ideal cases protect sales after generics enter. However in order to achieve this companies must focus increasingly on demonstrating provable benefits, ideally in head to head trials against the original product.

$3900 Read More

Looking at Senior Long-term Care - Where will the market go?

In the last 50 years, long-term care facilities in the US have changed significantly. Many facilities are now Continuing Care Retirement Communities (CCRCs), offering a continuum of care from Independent Living to Assisted Living to Skilled Nursing. Memory Care facilities, for those with Alzheimers Disease or Dementia are often separate facilities, but may be part of a larger CCRC campus. Long-term care is becoming increasingly important as a market with the US population aging. Over 65s are now the fastest growing population group in the US. With the Baby Boomer generation only just beginning to turn 65 in 2011, the next 20 years will see tremendous growth in the long-term care population.

$3900 Read More

Risk Evaluation and Mitigation Strategies - Adaptation in an evolving system

As an evolution of this process, the agency established the Risk Evaluation and Mitigation Strategies (REMS) program in 2008. Products can be approved with a Medication Guide only REMS, a Communication Plan REMS which incorporates a Medication Guide together with educational materials for providers or it can require Elements to Assure Safe Usage (ETASU). There has been substantial criticism of the current REMS system from pharmaceutical companies, as well as from providers and dispensers. The FDA is moving to address some of these criticisms by trying to establish greater standardization across the system.

$3900 Read More

Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation

Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations is significant.

$6995 Read More

Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth

GBI Research, the leading business intelligence provider, has released its latest research, ""Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth"", which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and

$4995 Read More

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation

The Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) pipeline consists of 84 molecules across all stages of development. GBI Research’s analysis revealed a high degree of innovation and diversity in this indication, with 70% of the pipeline being first-in-class products, acting on 13 first-in-class targets. This exceptional first-in-class innovation is largely due to the high number of first-in-class products solely targeting the dystrophin gene, which is the primary genetic cause of DMD and BMD. 

$6995 Read More

Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability.

$4995 Read More

Dexmedetomidine - Comprehensive patent search

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.  Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on.

$9300 Read More

Ferric carboxymaltose - Comprehensive patent search

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.  Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on.

$6200 Read More

Lanreotide - Comprehensive patent search

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.  Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on.

$9300 Read More

Vildagliptin - Comprehensive patent search

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.  Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on.

$7500 Read More

Cabozantinib - Comprehensive patent search

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.  Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on.

$7500 Read More

Nilotinib - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Nilotinib  Nilotinib indications: Treatment of Philadelphia chromosome positive chronic myeloid leukaemia, optionally in combination with erythropoietin, G-CSF, hydroxyurea or Anagrelide Nilotinib innovator: Novartis (Tasigna) Examples of information found in this online report include:

$1200 Read More

Ceftolozane - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Ceftolozane Ceftolozane indications: Treatment of serious Gram-negative bacterial infections Ceftolozane innovator: Cubist Examples of information found in this online report include: Includes key patent publications for 44 countries (see list below) Contains SPC protection for every EU state plus patent term extensions in other countries Data

$1200 Read More

Ceftobiprole - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Ceftobiprole Ceftobiprole indications: Treatment for complicated skin and skin structure infections Ceftobiprole innovator: Janssen (Zeftera, Zevtera) Examples of information found in this online report include: Includes key patent publications for 44 countries (see list below) Contains SPC protection for every EU state plus patent term

$1200 Read More

Deferasirox - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Deferasirox Deferasirox indications: Treatment of chronic iron overload due to blood transfusions or in patients with non-transfusion dependent thalassaemia; Management of chronic iron overload in transfusion-dependent anaemias Deferasirox innovator: Novartis (Exjade) Examples of information found in this online report include:

$1200 Read More

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Subscription to La Merie Publishing’s proprietary Antibody Database provides online access to information about more than 2,400 project entries for therapeutic antibodies on the market and in research & development. Pre-established and free search functions allow to identify antibodies according to their Technology (e.g. antibody-drug conjugate, bispecific, isotype, phage display) Target (e.g. Her2, CD20, TNF, PD-1/PD-L1) Pipelines (selected by target, therapeutic area, company, technology) Sales (for marketed antibodies) R&D Phase (clinical phases, market, preclinical) Territory (countrywise) Therapeutic Area (e.g. infectious, oncology, gastrointestinal)

$1705 Read More

Antibody Technologies and Attrition Rates - an industry analysis 2013

The report “Antibody Technologies and Attrition Rates – an industry analysis 2013” is based on the identification of the antibody generation technologies of 504 naked antibodies in clinical or market stages. Information was retrieved from scientific and corporate publications as well as from patent and legal literature. The report provides descriptive statistics of the 504 naked antibodies and their status during the study period of January 1, 2013 to February 28, 2013.

$2781 Read More

Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2013 Edition

The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope.

$2350 Read More

Risk Sharing and Other Forms of Managed Entry Agreements for Medicines, Worldwide

Managed entry agreements apply to an increasing number of new, innovative drugs in a growing number of markets. They are designed to share the risk between the manufacturer and the payer, consequent on uncertainties - usually at launch - about the product’s value (clinical- and cost-effectiveness), budget impact and/or utilisation to optimise performance, whilst at the same time allowing patient access. For many products considered costly they are almost essential to achieve reimbursement where health technology assessment is applied.

$1050 Read More

Japan Pharmaceutical Pricing & Distribution Market , 2012 Update

No serious pharmaceutical company can afford to ignore Japan, a $120 billion market, the second-largest in the world. It remains a tough and highly competitive market to crack, however, with the environment for developing and marketing medicines dominated by price.

$1400 Read More

Orphan Drugs Market in Europe: Pricing, Reimbursement, Funding & Market Access Issues, 2011 Edition

The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope.

$2300 Read More

Market Access Korea: Breaking into the Developed World's Fastest Growing Pharmaceutical Market

South Korea as a country has been an economic success story and the origin of much cutting edge technology, but its pharmaceutical market can now also be given ‘Asian tiger’ status. The past four years have seen total sales growth of 15.6%, 13.5%, 12.4% and 13.8% respectively. IMS forecasts CAGR of 6.5% from 2010 through 2015, making Korea the fastest growing developed market for medicines in the world.

$1380 Read More

Asia-Pacific Orphan Drugs Market : From Designation to Pricing, Funding & Market Access

A major new report Orphan Drugs in Asia-Pacific: From designation to pricing, funding and market access focuses on five developed markets in the region: Japan, South Korea, Taiwan, Singapore and Australia. Each has passed specific measures to promote the development, registration and/or commercialisation of rare disease treatments.

$2320 Read More

OTC Drugs Markets in China

China's demand for OTC Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades.

$4000 Read More

Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

Pharmaceutical Industry China – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 199 tables & figures within 153 pages.

$2754 Read More

Pharmaceutical Market China Q2 2013

Pharmaceutical Industry China Q2·2013 – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments.

$2700 Read More

Pharmaceutical Market India Q2 2013

Pharmaceutical Market India: A Comprehensive Industry Analysis provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 330 tables & figures.

$2700 Read More

Personalized Medicine & Companion Diagnostic Market Q2 2013

Personalized Medicine and Companion Diagnostic Market- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment” provides you with a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 261 tables & figures over 205 pages.

$3766 Read More

Pharmaceutical Industry in China Q3 2013 - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

This report tackles not only global pharmaceutical company interest in China but also home grown companies and their battle for position. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.

$2754 Read More

India Pharmaceutical Market: A Comprehensive Industry Analysis Q3 2013

Pharmaceutical Market: India, A Competitive Industry Analysis Q3 2013” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities. 

$2593 Read More

BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 154 tables & figures.

$2593 Read More

Personalized Medicine- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 239 tables & figures.

$3617 Read More

Optimizing Treatment for Bone Metastases in Patients with Advanced Cancers

Understand current practice patterns related to bone metastases in patients with advanced cancers. Patient specific unfolding case scenarios presented to 174 high-prescribing oncologists on the treatment of bones metastases in patients with advanced stages of cancer including breast, renal cell carcinoma, and prostate. The survey was presented for their responses on clinical decisions.

$2999 Read More

US Oncologist Survey: Optimizing Treatment for Stage IIIA Asymptomatic Indolent Lymphoma

Patient specific case scenario on advanced non-Hodgkin’s lymphoma in a situation involving a patient with Stage IIIA Asymptomatic Indolent Lymphoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals.

$2999 Read More

US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma

Two patient specific case scenarios on advanced non-Hodgkin’s lymphoma involving patients with a) relapsed large cell lymphoma and b) large cell lymphoma with compromised cardiac function that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal.

$2999 Read More

US Oncologist Survey: Optimizing Treatment for Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

A patient specific case scenario on advanced non-Hodgkin’s lymphoma involving a patient with stage IV follicular B-cell that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal: Decisions in treatment and tests through disease stages Factors influencing their decisions Barriers to optimal patient care Confidence in treatment

$2999 Read More

US Oncologist Survey: Optimizing Treatment for Advanced Non-Hodgkin's Lymphoma

Experience real patient situations that progressively unfold, presented to a representative sample of 158 US oncologists who manage 11 or more patients monthly with non-Hodgkin’s lymphoma. Oncologists were presented with four patient case scenarios and asked to respond to open-ended questions concerning their choices of treatment regimens, factors that influenced their decisions, and barriers to optimal patient management. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of specific patient types.

$8900 Read More

Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey

A patient specific case scenario on advanced lung cancer in a situation involving a smoker with squamous cell that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals: Decisions in treatment and tests through disease stages Factors influencing their decisions Barriers to optimal care Confidence in treatment.

$2999 Read More

Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma: Clinical Insights from a US Oncologists' Survey

A patient specific case scenario on advanced lung cancer in a situation involving a patient with EGFR Mutation Positive Adenocarcinoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals.

$2999 Read More

Advanced Lung Cancer in Patient Light Smoker with Lung Adenocarcinoma: Clinical Insights from a US Oncologists' Survey

A patient specific case scenario on advanced lung cancer in a situation involving a patient that is a light smoker with lung adenocarcinoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals: Decisions in treatment and tests through disease stages Factors influencing their decisions Barriers to optimal patient care Confidence in treatment

$2999 Read More

US Oncologist Survey: Optimizing Treatment for Advanced Lung Cancer

Experience real patient situations that progressively unfold, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced lung cancer.

$8900 Read More

Advanced Prostate Cancer with Increased PSA and Adenocarcinoma: Clinical Insights from a US Oncologists' Survey

Progressively unfolding patient situation, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. 

$2999 Read More

US Oncologist Survey: Optimizing Treatment for Advanced Prostate Cancer

Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US Oncologists on the treatment of patients with advanced prostate cancer.

$8900 Read More

US Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer

Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. 

$6900 Read More

Triple Negative Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey

Primary research that presents a patient specific case scenario unfolding throughout the report, to 174 high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their open responses on specific clinical decisions. 

$2999 Read More

Triple Positive Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey

Primary research that presents a patient specific case scenario unfolding throughout the report, to 174 high-prescribing oncologists on Triple Positive Metastatic Breast Cancer for their open responses on specific clinical decisions. 

$2999 Read More

US Oncologist Survey: Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer

Patient specific case scenarios that unfold throughout the report, presented to 174 high-prescribing oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for their open responses on clinical decisions, distributed and collected December 15, 2010 and January 10, 2011. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment. 

$2999 Read More

US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. 

$8900 Read More

Regenerative Medicine Market - Global Trends, Estimates and Forecasts, 2013-2019

Global Regenerative Medicine market is estimated to reach US$24.7 billion by 2017. Regenerative Medicine in Orthopedics market is projected to reach US$10.3 billion by 2017, growing at a CAGR of 12.2% for the analysis period 2013-2019 respectively. Skin/Integumentary and Urology together account for approximately 25.97% (2016) of the market are expected to support the Regenerative Medicine Industry going forward.

$4710 Read More

Research Report on Chinas Veterinary Active Pharmaceutical Ingredient and Chemical Preparation Industry

The scale of China's veterinary farming industry keeps on increasing with a high-density farming pattern, which will make the prevention of veterinary epidemics in China become increasingly severe. As active pharmaceutical ingredients and chemical preparations are more and more widely used in veterinary farming industry, China's veterinary active pharmaceutical ingredients and chemical preparations industry develops rapidly.

$6000 Read More

Global Vitamin C Supply Chain and Future Pricing Trends

The management report, The Global Vitamin C Supply Chain & Future Pricing Trends, is a result of 5-months’ study on global, particularly the Chinese raw vitamin C industry and was published in early December 2008.

$5000 Read More

Diagnostic Electrophysiology (EP) Catheters - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2012-2018

BRICSS Diagnostic Electrophysiology Catheters market value is expected to reach US$710 million by 2016, primarily supported by the product types - Conventional EP Diagnostic Catheters,Advanced EP and Diagnostic Cathetersand Ultrasound EP Diagnostic Catheters. China accounts for nearly 25% of the market share and India claims more than 25%. In terms of CAGR, China is the fastest growing region while India and South Korea are just behind. Among the product types, Conventional EP Diagnostic Catheters market value indicates more than 50% by 2015 leaving the rest of the market to Advanced EP Diagnostic Catheters and Ultrasound EP Diagnostic Catheters.

$2500 Read More

Mauritius Pharmaceuticals Report

The Mauritius Pharmaceuticals Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

$1295 Read More

The Pharmaceutical Market: Namibia

amibia has many of the qualities exhibited by frontier pharmaceutical markets: very low percapita spending on medicines, limited access to healthcare facilities, a high prevalence of communicable diseases and constrained ability to pay for advanced therapeutics. Nevertheless, due to low growth rates in developed states, multinational drugmakers are increasingly displaying interest, albeit tentatively, in Namibia.

$1295 Read More

The Pharmaceutical Market: Puerto Rico

The outcome of the upcoming elections is expected to assist in shaping the development of Puerto Rico's healthcare and pharmaceutical markets, depending on the direction of the new governor's economic policies. Nevertheless, we do not expect a return to the historically-high annual rates of pharmaceutical spending, especially as the government now covers less than 40% of theterritory'soverall healthcare spending.

$1295 Read More

The Pharmaceutical Market: Oman

Oman's commendable public healthcare system and high-class tertiary and quaternary care hospitals will increase the uptake of medical tourism by GCC citizens. The Omani pharmaceutical market will continue to remain heavily reliant on imports due to the costly need to source raw ingredients for local manufacturing and lack of R&D backing. However, despite t he strict drug pricing system, we are likely to see more multinational companies penetrating the market and expanding volume sales, by addressing the increasing burden of non-communicable diseases in the country.

$1295 Read More

The Pharmaceutical Market: Colombia

Improvements in Colombia's pharmaceutical re gulation system will expand local patients' access to medicines. However, it will also p ut pricing pressure s on drugmakers, and promote the use of generic versions, which will undermine the growth of patented drug market. Nevertheless, BMI expects more foreign pharmaceutical co mpanies to invest in Colombia, capitalising on the country's strong long-term growth prospects.

$1295 Read More

Nanotechnology for Drug Delivery : Global Market for Nanocarriers

Nanocarriers will account for 40% of a $136 billion nanotechnology-enabled drug delivery market by 2021. We forecast the total market size in 2021 to be US$136 billion, with a 60/40 split between nanocrystals and nanocarriers respectively, although developing new targeted delivery mechanisms may allow more value to be created for companies and entrepreneurs.

$1995 Read More

The Pharmaceutical Market: Bangladesh

While geographic diversification and investment into the pharmaceutical and healthcare sector of emerging economies, such as Bangladesh, may be a favourable strategy for any multinational pharmaceutical company - it is vital that a company recognises both the rewards and the risks present in a market.

$1295 Read More

The Pharmaceutical Market: Kazakhstan

Kazakhstan ' s pharmaceutical market remains the most accessible, transparent and, from a legislative point of view, progressive in Central Asia. In terms of market size, its potential is limited by its relatively small population (15mn) and logistical challenges. In the short term, Kazakhstan ' s market development is driven by a balanced policy of import substitution and integration into regional (Customs Union) and global (World Trade Organisation) systems.

$1295 Read More

The Pharmaceutical Market: Sudan & South Sudan

Sudan and South Sudan's will continue to be of least interest to foreign pharmaceutical firms in the Middle East and North Africa region as the countries are plagued by high inflation, fiscal constraints and underdeveloped non-oil economies. Political risk remains elevated as many disputes between them are still unresolved.

$1295 Read More

Nanotechnology in Drug Delivery: Global Markets

The report provides an in-depth presentation of recent developments (2000-2010) in nanoparticle-enabled DDS and future opportunities (2011-2021).  Persons with a financial or academic interest in the pharmaceutical industry who want to learn how advances in nanotechnology research and development will impact the economics of the pharmaceutical market will benefit most from this report.

$1995 Read More

The Pharmaceutical Market: Taiwan

We continue to view Taiwan as a challenging market for multinationals, mostly on account of the difficult pricing and reimbursement environment, which is due to undergo further changes. Specifically, as part of the Second Generation National Health Insurance (NHI) programme, which becomes effective in 2013, a new reimbursement system is expected to be rolled out in Taiwan.

$1295 Read More

The Pharmaceutical Market: Myanmar

Despite its small size, Myanmar's pharmaceutical market offers drugmakers strong revenue-earning opportunities. Generic and over-the-counter drug companies in particular stand to benefit, as the population's per capita expenditure on pharmaceuticals and healthcare remains low but set to rise.

$1295 Read More

Nanotechnology in Drug Delivery 2011-2021

The healthcare market is poised to see some of the earliest benefits of nanotechnology. Over the next decade, it will be one of nanotech's highest growth sectors. Targeted drug delivery therapies for the treatment of cancer is one of the most commonly cited nano-healthcare benefits.

$5000 Read More

The Pharmaceutical Market: Lebanon

Although this quarter has seen a number of regulatory initiatives taken by the Lebanese Minister of Health, Ali Hassan Khalil , to improve the state of the pharmaceutical industry, we maintain that a multilateral approach is required to improve foreign direct investment (FDI) in to the country and that , in the short to medium term, investment will be deterred and medical tourism revenue diminished by wider macroeconomic and political vulnerabilit i es.

$1295 Read More

The Pharmaceutical Market: Turkey

The cooling economic environment and the weakening lira has moderated optimistic forecasts on the Turkish pharmaceutical market, especially as the government is the single largest reimburser of pharmaceuticals, covering 80-85% of total drug expenditure through various insurance and immunisation schemes.

$1295 Read More

The Pharmaceutical Market: Zambia

The majority of investment in Zambia's healthcare market stems from international aid agencies - so the news that the government has increased its allocation for healthcare spending in the 2013 budget will be well received by both NGOs and international investors as a sign that Zambia is taking its commitment to healthcare seriously. The country suffers from a burden of both communicable and non-communicable diseases, with a high incidence of HIV and AIDs, malaria, and problems such as cholera emerging in Q4 12, but it is making progress.

$1295 Read More

The Pharmaceutical Market: The Netherlands

While the Netherlands is a low-risk market from the point of view of multinational drugmakers, the country's modest per capita expenditure on pharmaceuticals relative to other Western European countries is an issue. Another challenge facing drugmakers is cost-containment, which will only intensify as the Netherlands enters a period of slower economic growth. In fact, as we warned , the Dutch authorities recently introduced a new scheme - reimbursement for medicines that prove therapeutically ineffective will be reclaimed from the manufacturer - to reduce public healthcare costs.

$1295 Read More

The Pharmaceutical Market: Germany

While the Arzneimittelmarkt-Neuordnungsgesetz ( AMNOG ) legislation will compress drug companies' revenue-earning opportunities in Germany, we believe the government's decision to make the final reimbursement prices of medicines sold in the country publicly available, and the use of reference pricing across the region, will also lead to price reductions in other countries, providing an aggregation of pricing pressures on companies operating throughout Europe.

$1295 Read More

The Pharmaceutical Market: Austria

The macroenvironment for the Austrian pharmaceutical industry is positive. Economic recovery is strengthening, with modest GDP real growth projected in 2012 and 2013. However, the EIU projects that Austria will be affected by the expected euro zone recession. Legally, laws on intellectual property and patent provision are in line with WTO/TRIPS regulations. Healthcare expenditure has continued its steady growth in recent years.

$1295 Read More

The Pharmaceutical Market: South Africa

The government drive to support local production and reduce the country's reliance on imports, in addition to global epidemiological and demographic trends, are all positive factors contributing to long-term growth in the pharmaceutical market. However, deep segregation between private and public healthcare facilities continues to leave the vast majority of the population without medical care.

$1295 Read More

The Pharmaceutical Market: United Arab Emirates

The United Arab Emirates'healthcare and pharmaceutical markets continue to be thestrongest in the region.Its growth prospects arestrong -we forecast high single-digit CAGRsover the course of our 10-year forecast period. Several factors are driving growth: incomes are high, as isthe UAE's expatriate population.These elements combine to increase private healthcare expenditure and demand for innovative drugs.

$1295 Read More

The Pharmaceutical Market: Qatar

According to recent reports in The Gulf Times, Qatar will have four new drug manufacturers by the end of Q113. The drugmakers will reportedly import their raw materials and produce tablets, syrups and injectables. It is anticipated the drug manufacturers will (in our view eventually) help curb reliance on imports and lower prices of retail medicines in the country as a result of increased local competition, according to Dr Aisha al-Ansari of the Supreme Council of Health Pharmacy and Drug Control Department (SCH).

$1295 Read More

The Pharmaceutical Market: Slovakia

Slovak Prime Minister Robert Fico plans to unify the country'sprivate and public health insurance funds into a single state-owned insurer, but there is likely to be a lengthy negotiation and a legal battle before this is realised. We do not expect either of the two private insurers - Dôvera or Dutch-owned Union - will surrender their businesses without a fight, with Union in particular well-placed toopposethe move, potentially invoking EU law on protectionism.

$1295 Read More

Pharmaceutical